Loading
Giving cisplatin during pelvic radiotherapy nearly halved the risk of death compared with radiotherapy with hydroxyurea in locally advanced cervical cancer, establishing weekly cisplatin chemoradiation as the worldwide standard.
Phase 3 trial of 526 women with stage IIB to IVA cervical cancer randomised to radiotherapy with weekly cisplatin, with cisplatin plus fluorouracil and hydroxyurea, or with hydroxyurea alone.
Both cisplatin arms improved progression-free and overall survival compared with hydroxyurea (relative risk of death 0.61 and 0.58), and weekly cisplatin was the least toxic, becoming the standard regimen.
Weekly cisplatin with external beam radiotherapy and brachytherapy remains the backbone of curative treatment for locally advanced cervical cancer; INTERLACE and KEYNOTE-A18 build on it.